



Solv4U

Solv4U technology partnerships


SOLVE THE UN(DIS)SOLVABLE



Solve the un(dis)solvable
www.solv4u.com

Solubility enhancement

Marinosolv® enables the solubilization of APIs from mainly BCS (biopharmaceutics classification system) classes II and IV. Marinomed has validated the technology through its own clinically validated and well tolerated product development projects, improving established APIs. Furthermore, several compounds have been solubilized successfully in different client projects.



Using Marinosolv® as formulation technology offers several new applications for highly insoluble substances in eyes, lungs, as well as several other sensitive target tissues, resulting in high local activity and low systemic side effects. Marinosolv® may be used for re-formulation and/or re-purposing of established API's enabling life cycle extension of locally applied, locally acting drugs but also for systemic administration routes.

Application routes & Dosage forms



Local
(e.g. intranasal/ocular)



Systemic
(e.g. oral/intravenous)



Semi-solids




Liquid solution



Mode of action

Saponins (e.g., Escin, Glycyrrhizin), stability enhancers (e.g., Dexpanthenol) and selected solvents are used as solubility-enhancing agents in aqueous formulations. The different constituents of the Marinosolv® matrix are individually composed in buffered solutions for an optimized formulation of each drug substance.

Marinosolv® formulation & solubilization of water-insoluble API



Marinosolv® increases solubility

Enhances permeation of API into target tissue

Improves bioavailability of API

Patients will benefit from

Faster onset of action

Dose reduction

Lower possible side effects

Well-tolerable local and systemic administration

Manufacturers will benefit from

Easily scalable process

Increased sustainability of manufacturing

Option for preservative-free formulations

Aseptic filtering of formulation

Suspension in water/buffer




Solution enabled by Marinosolv®





Support from early stage to product manufacturing

Solv4U partnerships address formulation challenges in small molecules and peptide drug development and rely on a clinically proven technology. Formulations are customized for individual compounds to achieve an optimal result. Formulation services include a feasibility study with clearly defined scope and timelines. All formulations are custom-made and designed in close cooperation with our clients, taking into consideration the physicochemical uniqueness of each compound as well as the requirements for later development stages and manufacturing.



About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with globally marketed therapeutics and a growing development pipeline. The Company focuses on the development of innovative products based on two patent-protected technology platforms, Marinosolv® and Carragelose®. Marinomed is listed on the Vienna Stock Exchange (VSE: MARI).



For more information, please contact our Business Development team:
E-Mail: bd@marinomed.com
Tel: +43 2262 90300
www.solv4u.com

Follow us on



Marinomed Biotech AG, www.marinomed.com
Hovengasse 25, 2100 Korneuburg, Austria



Solv4U

Solve the un(dis)solvable
www.solv4u.com